Pharmaceuticals for treating obesity
CA 2386750 A1 · Owner: Leibowitz, Mark D. · Inventors: Doebber, Thomas W.; Zhang, Bei B.; Moller, David E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds which are antagonists of strong PPAR-gamma agonists such as , rosiglitazone, and are also partial agonists of the PPAR-gamma receptor are , active agents for correcting or reducing obesity. For example 1-(p-, chlorobenzyl)-5-chloro-3-thiophenylindole-2-carboxylic acid is characterized , as being a potent and selective ligand for PPAR-gamma which has partial agonist (<30 % maximal effects relative to rosiglitazone) and antagonist activity in cell-free and cell-based assays for the PPAR-gamma receptor. The compound is a potent agent for reducing obesity and insulin resistance in fatfed C57BL/6J mice. This compound and other PPAR-gamma antagonists/partial agonists and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 19, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 19, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 19, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.